Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries NewAmsterdam Pharma Company N.V. - Warrant (NQ: NAMSW ) 10.20 UNCHANGED Streaming Delayed Price Updated: 3:59 PM EST, Nov 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 10.20 Bid (Size) 7.000 (1) Ask (Size) 10.49 (1) Prev. Close 10.20 Today's Range 10.20 - 10.20 52wk Range 1.710 - 14.67 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 01, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November October 28, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire Performance YTD +234.43% +234.43% 1 Month +27.50% +27.50% 3 Month +70.00% +70.00% 6 Month -1.21% -1.21% 1 Year +385.71% +385.71% More News Read More NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 04, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 06, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September August 30, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results August 07, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 02, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia July 29, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 July 26, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors July 18, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors July 08, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office June 11, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June May 29, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings May 21, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results May 09, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 May 02, 2024 From NewAmsterdam Pharma N.V. Via GlobeNewswire NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease April 09, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer April 01, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress March 25, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD March 12, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update February 28, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March February 26, 2024 From NewAmsterdam Pharma N.V Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
